Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470628 | PMC |
http://dx.doi.org/10.3389/fmed.2023.1268976 | DOI Listing |
Oncol Ther
January 2025
Coordinator of the International Head and Neck Scientific Group, Padua, Italy.
Introduction: Laryngeal chondrosarcoma (CS) is a rare indolent malignant tumor. High-grade (G3), dedifferentiated (DD), and myxoid (MY) CSs are considered more aggressive subtypes due to their metastatic potential and relatively poor outcomes. The aim of this systematic review is to evaluate treatment modalities and survival outcomes in patients affected by these rarer CS subtypes.
View Article and Find Full Text PDFBMJ Case Rep
January 2025
Pediatrics, University of California Irvine, Irvine, California, USA
Expert Rev Anticancer Ther
January 2025
Division of Pancreatic Surgery, Pancreas Translational & Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Cancer Biol Med
January 2025
Department of Oncology, Fifth Medical Center of the Chinese PLA General Hospital, Beijing 100071, China.
Oncol Rep
February 2025
Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China.
Following the publication of this paper, it was drawn to the Editor's attention by a concerned reader that certain of the western blot data shown in Fig. 4 on p. 521 were strikingly similar to data that had already appeared in a pair of figures in a previously published article written by different authors at different research institutes in the journal .
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!